Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism
Open accessThe DOI matches its Crossref record; 84 of the 85 references it cites were found in a registry or an index; 11 of the 90 sources its claims cite were checked for support.
Abstract
Polycystic ovary syndrome (PCOS) is a heterogeneous and extremely common disease with symptoms that vary with the age of the patient, typically characterized by hyperandrogenism, chronic oligo-anovulation, and/or several metabolic disorders. The syndrome includes various phenotypes, and the pathogenesis is multifactorial, often involving insulin resistance. This feature is closely related to ovarian dysfunction, inflammation, hyperandrogenism, and metabolic disorders, which characterize and complicate the syndrome. Therapy currently considers both lifestyle improvements and medications, and must be tailored on a case-by-case basis. To date, the published studies have not arrived at a definition of the most suitable therapy for each individual case and many of the drugs used are still off-label. In this review, we discuss some controversial diagnostic and therapeutic aspects of PCOS, such as the role of insulin resistance, inflammation, and hyperandrogenism. We also evaluated the advantages and disadvantages of contraceptive therapy and antiandrogens.
Overview
CoChat Summary
TL;DR
This review discusses controversies in the pathogenesis, diagnosis, and treatment of polycystic ovary syndrome (PCOS), focusing on insulin resistance, inflammation, and hyperandrogenism. It argues that therapy must be individualized and that, apart from combined oral contraceptives (COCs), most drugs used for PCOS remain off-label, with larger and longer-term studies needed.
Key findings
- PCOS prevalence varies by diagnostic criteria: 4–8% by NIH/NICHD criteria and approximately 18% by Rotterdam criteria; the Rotterdam criteria are endorsed by a recent international evidence-based guideline.
- Insulin resistance is common in PCOS, worsened by hyperandrogenism-related adipose tissue accumulation, and compensatory hyperinsulinemia stimulates ovarian theca androgen production and decreases hepatic SHBG synthesis, increasing total and free androgens.
- Chronic low-grade inflammation is associated with increased white blood cell count, CRP, IL-6, IL-18, monocyte chemoattractant protein-1, and macrophage inflammatory protein-1; aldosterone and the aldosterone/renin ratio are often increased in PCOS and may accentuate inflammation and metabolic/cardiovascular disorders.
- Treatment should start with lifestyle improvement; metformin, inositols (with a MYO:DCI ratio of 40:1 described as most effective), GLP-1 receptor agonists, and SGLT2 inhibitors are discussed, while COCs and antiandrogens have benefits and risks; spironolactone is preferred among antiandrogens because it also has anti-inflammatory action.
Methods
- Narrative review of published literature on PCOS pathogenesis, diagnosis, and treatment, with emphasis on insulin resistance, inflammation, and hyperandrogenism.
- The paper synthesizes prior studies and guidelines, including diagnostic criteria, PCOS phenotypes A–D, androgen measurement issues, insulin resistance assessment, and therapeutic options.
- No primary data collection, new patient sample, or systematic meta-analysis is described.
Limitations
- Stated: many PCOS drugs are off-label; more randomized controlled trials and long-term studies are needed; larger samples are needed to evaluate new therapies and inflammation in adipose tissue; microbiome role requires further study; studies of third-generation contraceptives are short-term, discordant, and often limited in patient numbers.
- Evident from the text: as a narrative review, it does not report a systematic search strategy, formal risk-of-bias assessment, or new empirical data, so conclusions rely on interpretation of cited literature.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
9 Valid · 7 Not valid · 66 Not checked · 16 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The administration of drugs with anti-androgenic activity improves insulin resistance [26].”
§ Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism > 4. The Pathogenetic Role of Hyperandrogenism in PCOS
What the sources say
- Disputedcites [26] Armanini, 2016, Spironolactone in the treatment of polycystic ovary syndrome, Expert Opin. Pharmacother. sourceExperimental — accuracy not yet measured
Section 3 (page unavailable) discusses hormonal contraceptives containing progestins with antiandrogenic activity, but says the available data do not demonstrate a positive or negative effect on insulin resistance. The paper discusses spironolactone’s benefits for androgen-related symptoms; it does not establish the claimed improvement in insulin resistance. (LLM, conf=0.82)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“insulin resistance, a very common condition in PCOS, which is worsened by hyperandrogenism-related adipose tissue accumulation [3] and is involved in both the pathogenesis and the progression of the disease [4].”
§ Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism > 1. Introduction
What the sources say
- Supportedcites [3] Dumesic, 2020, Endocrine-metabolic dysfunction in polycystic ovary syndrome: An evolutionary perspective, Curr. Opin. Endocr. Metab. Res. source
The Insulin resistance section states that 60–95% of women with PCOS have insulin resistance, supporting the description of it as very common. (LLM, conf=0.95)
- Not checked yetcites [4] Dunaif, 2012, Insulin resistance and the polycystic ovary syndrome revisited: An update on mechanisms and implications, Endocr. Rev. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Another important pro-inflammatory agent involved in the pathogenesis of PCOS is adipose tissue [18].”
§ Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism > 3. The Pathogenetic Role of Inflammation in PCOS
What the sources say
- Partly supportedcites [18] Makki, 2013, Adipose tissue in obesity-related inflammation and insulin resistance: Cells, cytokines, and chemokines, ISRN Inflamm. sourceExperimental — accuracy not yet measured
Our copy supports the general half of the claim: Section 1 states that obesity is a proinflammatory condition and that 'white adipose tissue (WAT) is the key site mediating systemic inflammation,' and Section 1.1 that obese adipose tissue mainly releases proinflammatory cytokines (TNF-α, IL-6, leptin, resistin...) contributing to insulin resistance. PCOS appears only once, in Section 1, where 'polycystic ovarian diseases' is listed among metabolic diseases for which excess adiposity is an established risk factor (citing ref [1]) — a risk-factor statement, not a pathogenic mechanism. The source nowhere attributes to adipose tissue a pro-inflammatory role in the pathogenesis of PCOS specifically; its scope is obesity-induced inflammation and insulin resistance/T2D (Section 3, Concluding Remarks). The PCOS-specific causal/pathogenic part of the citing sentence is unsupported by this source. (LLM, conf=0.78)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Ideally, a progestin with the lowest possible androgenic action such as cyproterone acetate, chlormalidone, and drospirenone should be used. However, they have been associated with increased risk of venous thrombosis [65,66,67].”
§ Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism > 6. Controversies in the Treatment of PCOS > 6.2. Hormonal Contraceptives
What the sources say
- Not checked yetcites [65] Bird, 2013, Drospirenone and non-fatal venous thromboembolism: Is there a risk difference by dosage of ethinyl-estradiol?, J. Thromb. Haemost. source
- Partly supportedcites [66] Cushman, 2004, Estrogen plus progestin and risk of venous thrombosis, JAMA sourceExperimental — accuracy not yet measured
The COMMENT section reports increased venous-thrombosis risk with estrogen plus progestin in postmenopausal women. But the Participants section identifies the studied progestin as medroxyprogesterone acetate; the paper does not establish the claimed association for cyproterone acetate, chlormalidone, or drospirenone, or address their androgenic action. Page numbers are unavailable in our copy. (LLM, conf=0.84)
- Partly supportedcites [67] Gronich, 2011, Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: A population-based cohort study, CMAJ sourceExperimental — accuracy not yet measured
The Results report increased venous-thrombosis risk with drospirenone-containing contraceptives relative to second- and third-generation contraceptives. They do not establish the same association for cyproterone acetate or chlormadinone; the Results explicitly say the chlormadinone sample was too small to analyze. The source therefore supports the risk claim for drospirenone, but not for all three named progestins. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In particular, the most studied medication is metformin, which seems to positively influence microbiota diversity and composition [61].”
§ Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism > 6. Controversies in the Treatment of PCOS > 6.1. Insulin Sensitizers
What the sources say
- Partly supportedcites [61] Montandon, S.A., and Jornayvaz, F.R. (2017). Effects of antidiabetic drugs on gut microbiota composition. Genes, 8. sourceExperimental — accuracy not yet measured
Section 3 (Discussion) describes metformin as the most studied medication and reports increases in potentially beneficial bacteria, supporting the composition part. But Section 2.2 (Biguanides) says its effects on diversity are diet-dependent and reports decreased bacterial diversity in mice on a high-fat diet. The paper therefore does not support an unqualified positive effect on diversity. (LLM, conf=0.88)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
48 more claims · 1 with their cited sources checked
Create a free account to see all 98 claims and to verify the 79 references still open.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 8
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, chronic low-grade inflammation is commonly observed in this population, contributing to metabolic dysregulation and an increased risk of comorbidities such as T2DM and cardiovascular disease13.”
From Cross-sectional study of the relationship between dietary inflammatory index and inflammatory hormonal and metabolic profiles in polycystic ovary syndrome (2025) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, myoinositol might improve oocyte and embryo quality [5] by encouraging translocation of GLUT4 to the plasma membrane in order to increase glucose uptake [53] and promote aromatase activity.”
From Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials (2023) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hyperinsulinaemia, however, can contribute to certain obesity complications or related diseases, including hormonal disorders related to sex hormones and cancer (ie, mitogenic effect of insulin).98,99”
From Definition and diagnostic criteria of clinical obesity (2025) · cites this paper as [98]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In women, hormonal dysfunction of adipose tissue and hyperinsulinaemia (which can act as a gonadotrophin) from insulin resistance constitute the main links to development of functional hyperandrogenism or polycystic ovary syndrome.98”
From Definition and diagnostic criteria of clinical obesity (2025) · cites this paper as [98]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“On the other hand, insulin resistance (IR) has a central role in its pathogenesis [5–7].”
From Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials (2023) · cites this paper as [5]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) · Human Reproduction · doi:10.1093/humrep/deh098 · Cited by 6,138
A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum
Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6079 · Cited by 3,824 · cited 1×
“As direct assays to measure free testosterone are not entirely reliable, another useful tool for the assessment of biochemical hyperandrogenism is free testosterone calculated using the formula of Vermeulen and collogues [36].”
MethodThe Diagnosis of Polycystic Ovary Syndrome during Adolescence
Witchel, S. F., Oberfield, S., Rosenfield, R. L., Codner, E., Bonny, A., Ibáñez, L., Pena, A., Horikawa, R., Gomez-Lobo, V., Joel, D., et al. (2015) · Hormone Research in Paediatrics · doi:10.1159/000375530 · Cited by 3,113
Mechanisms of Insulin Action and Insulin Resistance
Petersen, M. C., & Shulman, G. I. (2018) · Physiological Reviews · doi:10.1152/physrev.00063.2017 · Cited by 3,028 · cited 3×
“In skeletal muscle, the inhib ion of phosphoi sitide-3 kinase nd phosp orylation of i sulin recep or sub trate 1 le ds to impaired insulin signali g by altering the GLUT-4 xpression and glucose uptake [6,7].”
BackgroundInsulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis*
Dunaif, A. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.6.0318 · Cited by 2,458 · cited 1×
“The second problem is related to the various methods of measurement (fasting insulin or after glucose loading), which do not correlate with what has been found using more accurate and sophisticated laboratory methods [40].”
MethodBonora, E., Targher, G., Alberiche, M., Bonadonna, R. C., Saggiani, F., Zenere, M. B., Monauni, T., & Muggeo, M. (2000) · Diabetes Care · doi:10.2337/diacare.23.1.57 · Cited by 2,456 · cited 1×
“In clinical practice, HOMA-IR is the most common test used in research studies to measure insulin resistance, as it has been shown to closely approximate the results of clamp studies over many years [41,42].”
ResultAzziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0178 · Cited by 2,143 · cited 1×
“However, this latter phenotype is not included among PCOS according to the Androgen Excess Society guideline, which suggests the presence of both hyperandrogenism and ovarian dysfunction [31].”
BackgroundDiamanti-Kandarakis, E., & Dunaif, A. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1034 · Cited by 1,947 · cited 2×
“In particular, insulin and LH act synergistically on the theca cells, stimulating ovarian androgen production [4].”
BackgroundLegro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., & Welt, C. K. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2350 · Cited by 1,919
Cited by
Items 301–324 of 324
Gut microbiota and polycystic ovary syndrome: Pathogenesis and novel therapeutic approaches
Zhu, T., Sha, Y., Wang, Q., Yang, H., & Liu, T. (2026) · Microbiological Research · doi:10.1016/j.micres.2026.128643
Sharma, N., Hachim, M. Y., Rizvi, S. S., Samreen, B., Inuwa, S., AbuHajjaj, T., Khamis, F. B., Alqutami, F., Han, A., Elrahman, I., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27156594
“It can impact a woman’s life, manifesting in puberty with menstrual irregularities, and continuing through reproductive years, leading to infertility, obesity and insulin resistance [3].”
Huang, Z., Xie, L., Zheng, X., Lu, Y.-J., Huang, J.-J., Zhou, J.-L., & Huang, M. (2026) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2026.109290
Romeo, P., Freger, S., Kalani, N., Shishkina, A., Aharoni, S., Shetty, R., & Leonardi, M. (2026) · Ultrasound in Obstetrics and Gynecology · doi:10.1002/uog.70289
pang, L., Wang, A., & Ni, M. (2026) · F&S Science · doi:10.1016/j.xfss.2026.07.005
Deciphering the Insulin Link: Exploring Metabolic Interplay in Polycystic Ovary Syndrome
Maqbool, M., Qadrie, Z., & Ashraf, H. (2026) · Tropical Journal of Pharmaceutical and Life Sciences · doi:10.61280/tjpls.v13i4.285
Albalawi, Y. A., & Mirghani, H. O. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1809000
Kashyap, P., Virvikram, Singh, B., Saini, G., Mandal, J. K., & Barwal, P. (2026) · BIO Web of Conferences · doi:10.1051/bioconf/202624900003
“( 15) In this research study, PCOS was simulated in rodents (Albino Wistar Rats) by administration of DHEA & Fructose.”
Ribeiro, V. B., da Silva, J. V. M. B., Lopes, I. P., Kogure, G. S., Philbois, S. V., dos Reis, R. M., Lara, L. A. D. S., & de Souza, H. C. D. (2026) · Revista Brasileira Ginecologia e Obstetrícia · doi:10.61622/rbgo/2026rbgo63
Saka, V. P., Goswami, A., Kumar, G. V. N., Das, A. K., Nanjappan, S. K., Dodoala, S., Sharma, M., Verma, D., Gupta, P., & Kaushik, S. (2026) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2026.100864
Shah, S., Parikh, A., Garg, S., & Mehta, T. (2026) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2026.2727678
Delibaş, Ö., Kutlu, B. Ö., & Saraydın, S. Ü. (2026) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2942-6488
Dutta, S., Daneshpazhouh, M., Muzammil, H. F., Al-Nuaimy, Y., Jalkhi, T., Pardasani, P., Shaju, R. E., Siby, A., Kalita, J. C., Rosas, I. M., et al. (2026) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2026.102777
Research Progress of Fat Factor Metrnl in Metabolic Diseases
Qian, W. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1693158
Vine, D. F., Moran, L., Teede, H. J., & Khomami, M. B. (2026) · Advances in Nutrition · doi:10.1016/j.advnut.2026.100734
Modern approaches to the diagnosis and treatment of polycystic ovary syndrome in adolescent girls
Sibirskaya, E. V., Sharkov, S. M., Karapetyan, A. A., & Чатикян, И. А. (2026) · M Ya Studenikin Russian Pediatric Journal · doi:10.46563/2026-1-1-53-60
The expanding frontiers of asprosin: beyond metabolism and mammals
Sathoria, P., Rai, U., & Roy, B. (2026) · Proceedings of the Indian National Science Academy · doi:10.1007/s43538-026-00927-3
Munir, Y. A., Aliyu, S. H., Salisu, I., Sani, A. K., Abdulaziz, A., Abdul, M., Sani, A. S., Ibrahim, M. S., Habib, A. I., Ibrahim, A., et al. (2026) · UMYU Scientifica · doi:10.56919/usci.2654.005
“The wide spectrum of clinical features and the large variability in these have complicated the understanding of PCOS as a one-pathway disorder and the creation of consistent and uniform treatments (Armanini et al ., 2022).”
Cano-González, C. N., Herrera-Estrada, M. D. L. L., Ríos-Peña, É. M., Torres-Martínez, A. D., Carmen-Jiménez, M. D., Hurtado-Santiesteban, A. P., Rodríguez-Cisneros, G., & Aguilar, C. N. (2026) · Spectroscopy Journal · doi:10.3390/spectroscj4040020
Bansal, V., Meena, P., Bansal, K., & Kaur, S. (2026) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20263507
Li, S., Liang, Y., Chen, G., Huang, Q., Yang, X., 李喜涛, Lu, L., Chen, F., & Yin, G. (2026) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2026.105088
Sudershan, A., Bala, A., Sheikh, B. A., Sudershan, S., Younis, M., & Kumar, P. (2026) · Biosciences Biotechnology Research Asia · doi:10.13005/bbra/3546
Prevalencia de resistencia a la insulina en pacientes con síndrome de ovario poliquístico
Pacheco, A. X. S., Castañón, A. W., & Jiménez, V. V. (2026) · Acta Médica Grupo Ángeles · doi:10.35366/124072
Zhao, H., Gui, P., Zhang, B., Wu, J., & Xie, Y. (2026) · Metabolic Brain Disease · doi:10.1007/s11011-026-02015-3
Metadata
- Authors
- Armanini, D., Boscaro, M., Bordin, L., & Sabbadin, C.
- Affiliations
- University of Padua (IT)
- Corresponding author
- Armanini, Decio
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-04-08
- Volume
- 23
- Issue
- 8
- Pages
- 4110
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC9030414
- OpenAlex
- W4224247712
- Semantic Scholar
- 6ba01eafb58b7f3a48fb9c3789a3b5c603a63b92
- Cited by
- 324
- References
- 85
- Citations by year
- 2026: 66 · 2025: 105 · 2024: 82 · 2023: 58 · 2022: 13
- FWCI
- 10.39
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Biology and Fertility
- Keywords
- polycystic ovary syndrome, insulin resistance, inflammation, hyperandrogenism, PCOS pathogenesis, PCOS diagnosis, PCOS treatment, androgen receptor antagonists, metabolic disorders, oligoanovulation, PCOS phenotypes
- MeSH terms
- Female, Humans, Inflammation, Insulin Resistance, Metabolic Diseases, Polycystic Ovary Syndrome, Hyperandrogenism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
